A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
Public ClinicalTrials.gov record NCT04544007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Study identification
- NCT ID
- NCT04544007
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 22 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 7, 2022
- Primary completion
- Jan 3, 2024
- Completion
- Nov 14, 2024
- Last update posted
- Mar 20, 2025
2022 – 2024
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham (Site 700) | Birmingham | Alabama | 35294 | — |
| Children's Hospital of Los Angeles | Los Angeles | California | 90027 | — |
| Children's National Medical Center (Site 775) | Washington D.C. | District of Columbia | 20010 | — |
| Children's Healthcare of Atlanta | Atlanta | Georgia | 30342 | — |
| Children's Lurie Hospital | Chicago | Illinois | 60611 | — |
| Lurie Children's Hospital of Chicago (Site 350) | Chicago | Illinois | 60611 | — |
| University of Chicago (Site 850) | Chicago | Illinois | 60637 | — |
| Washington University - St. Louis (Site 900) | St Louis | Missouri | 63110 | — |
| New York University Medical Center (Site 200) | New York | New York | 10016 | — |
| Cincinnati Children's Hospital Medical Center (Site 800) | Cincinnati | Ohio | 45229-3039 | — |
| Children's Hospital of Philadelphia (Site 750) | Philadelphia | Pennsylvania | 19096 | — |
| Childrens Medical Center - Univ. of Texas SW (Site 917) | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04544007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2025 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04544007 live on ClinicalTrials.gov.